Both models were then used to test, in a genomic DNA context, the efficacy of the U1-fix9, delivered with an AAV8 vector to overcome the effect of the splicing variant found in patients with Hemophilia B. The results showed the correction of the splicing pattern of human FIX mRNA, which translated into an increase in FIX protein expression levels. This evidence concerns the gene F9 and hemophilia B.